jakafi - ruxolitinib tablet
(Ruxolitinib)Incyte Corporation
Usage: Jakafi treats intermediate or high-risk myelofibrosis and polycythemia vera (in adults intolerant of or unresponsive to hydroxyurea). Also indicated for steroid-refractory acute and chronic graft-versus-host disease in adults and pediatric patients 12 and older.